Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 4/20 | 0.50 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.50 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.46 |
| ▸ | AGXT | P21549 | 2/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.39 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | MIF | P14174 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CES2 | O00748 | 1/20 | 0.38 |
| ▸ | CES1 | P23141 | 1/20 | 0.38 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15233233 | 0.97 | — | — | |
| SCHEMBL5110 | 0.97 | — | — | |
| SCHEMBL22165011 | 0.94 | IDO1 (0.50) | IDO1LOXL2TRPA1ALDH1A1TSHR | |
| SCHEMBL512431 | 0.94 | IDO1 (0.50) | IDO1LOXL2TRPA1ALDH1A1TSHR | |
| SCHEMBL8015172 | 0.89 | MAOB (0.52) | IDO1LOXL2TRPA1ALDH1A1TSHR | |
| SCHEMBL8885029 | 0.83 | NFE2L2 (0.54) | IDO1 | |
| SCHEMBL8885030 | 0.83 | NFE2L2 (0.54) | IDO1 | |
| SCHEMBL3103451 | 0.83 | IDO1 (0.41) | IDO1LOXL2TRPA1ALDH1A1TSHR | |
| SCHEMBL6336359 | 0.83 | LTA4H (0.46) | IDO1LOXL2AGXTMAOB | |
| SCHEMBL18166888 | 0.81 | IDO1 (0.39) | IDO1LOXL2TRPA1ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2137162-B1 | ORGANIC COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2018-08-01 | — | — | EP | disclosed |
| US-9409871-B2 | Pyridazinyl derivatives as SMO inhibitors | NOVARTIS AG (CH) | 2016-08-09 | — | — | US | disclosed |
| US-8859546-B2 | Picolinamide inhibitors of kinases | ABBVIE INC. (US) | 2014-10-14 | — | — | US | disclosed |
| EP-2665711-A1 | PICOLINAMIDE INHIBITORS OF KINASES | Abbvie Inc. (US) | 2013-11-27 | — | — | EP | disclosed |
| US-20130261299-A1 | PYRIDAZINYL DERIVATIVES AS SMO INHIBITORS | NOVARTIS AG (CH) | 2013-10-03 | — | — | US | disclosed |
| US-8536168-B2 | Benzyl and pyridinyl derivatives as modulators of the hedgehog signaling pathway | NOVARTIS AG (CH) | 2013-09-17 | — | — | US | disclosed |
| US-8481542-B2 | Pyridazinyl derivatives as smo inhibitors | NOVARTIS AG (CH) | 2013-07-09 | — | — | US | disclosed |
| EP-2318389-B1 | PYRIDAZINE DERIVATIVES AS SMO INHIBITORS | NOVARTIS AG (CH) | 2013-06-19 | — | — | EP | disclosed |
| US-20120289507-A1 | ORGANIC COMPOUNDS AS SMO INHIBITORS | NOVARTIS AG (CH) | 2012-11-15 | — | — | US | disclosed |
| US-20120190681-A1 | PICOLINAMIDE INHIBITORS OF KINASES | ABBOTT LABORATORIES (US) | 2012-07-26 | — | — | US | disclosed |
| WO-2010007120-A1 | PYRIDAZINE DERIVATIVES AS SMO INHIBITORS | NOVARTIS AG (CH) | 2010-01-21 | — | — | WO | disclosed |
| US-6410539-B1 | ANTICARCINOGENIC AGENTS | ASTRAZENCA UK LIMITED (GB) | 2002-06-25 | — | — | US | disclosed |
| US-20020058665-A1 | Imidazole derivatives and their use as farnesyl protein transferase inhibitors | ASTRAZENECA UK LIMITED | 2002-05-16 | — | — | US | disclosed |
| US-20020052376-A1 | Imidazole derivatives and their use as farnesyl protein transferase inhibitors | ASTRAZENECA UK LIMITED | 2002-05-02 | — | — | US | disclosed |
| US-6342765-B1 | COMPOUNDS THAT INHIBIT FARNESYLATION OF MUTANT RAS GENE PRODUCTS; TREATING DISEASES, ESPECIALLY CANCER, WHICH ARE MEDIATED THROUGH FARNESYLATION OF RAS | ASTRAZENECA UK LIMITED (GB) | 2002-01-29 | — | — | US | disclosed |
| EP-1025088-B1 | IMIDAZOLE DERIVATIVES AND THEIR USE AS FARNESYL PROTEIN TRANSFERASE INHIBITORS | ASTRAZENECA AB (SE) | 2001-09-05 | — | — | EP | disclosed |
| EP-1025089-A1 | IMIDAZOLE DERIVATIVES AND THEIR USE AS FARNESYL PROTEIN TRANSFERASE INHIBITORS | ZENECA LIMITED (GB) | 2000-08-09 | — | — | EP | disclosed |
| EP-1025088-A1 | IMIDAZOLE DERIVATIVES AND THEIR USE AS FARNESYL PROTEIN TRANSFERASE INHIBITORS | AstraZeneca UK Limited (GB) | 2000-08-09 | — | — | EP | disclosed |
| WO-1999020612-A1 | IMIDAZOLE DERIVATIVES AND THEIR USE AS FARNESYL PROTEIN TRANSFERASE INHIBITORS | ASTRAZENECA UK LIMITED (GB) | 1999-04-29 | — | — | WO | disclosed |
| WO-1999020611-A1 | IMIDAZOLE DERIVATIVES AND THEIR USE AS FARNESYL PROTEIN TRANSFERASE INHIBITORS | ZENECA LIMITED (GB) | 1999-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120190681-A1 | PICOLINAMIDE INHIBITORS OF KINASES | ALK, PKN2, ERBB2 | IDO1 2470/4885LOXL2 3142/4885TRPA1 739/4885 |
| US-20130261299-A1 | PYRIDAZINYL DERIVATIVES AS SMO INHIBITORS | SMO, SHH, GLI1 | IDO1 1994/4885LOXL2 1229/4885TRPA1 3517/4885 |
| US-20020058665-A1 | Imidazole derivatives and their use as farnesyl protein transferase inhibitors | FNTA, FNTB, RABGGTA | IDO1 2422/4885LOXL2 4165/4885TRPA1 4527/4885 |
| US-20120289507-A1 | ORGANIC COMPOUNDS AS SMO INHIBITORS | SMO, GLI1, SHH | IDO1 1102/4885LOXL2 929/4885TRPA1 2078/4885 |
| US-20020052376-A1 | Imidazole derivatives and their use as farnesyl protein transferase inhibitors | FNTA, FNTB, RABGGTA | IDO1 2367/4885LOXL2 4271/4885TRPA1 4521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.